Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8194
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Chengdu Kanghong Pharmaceuticals Group Co Ltd (Chengdu Kanghong Pharmaceuticals) is a pharmaceutical company that develops, manufactures and markets Chinese medicines, chemical drugs and biological products. The company offers products for the treatment of medical conditions related to central nervous system, digestive system, ophthalmic system, diabetic nephropathy, gastrointestinal, and others. It provides Chinese medicines for the treatment of hypertension and hyperlipidemia, aripiprazole for anti-psychotic treatment and venlafaxine hydrochloride sustained release tablets for the treatment of depression. Chengdu Kanghong Pharmaceuticals offers its products in the form of dispersible tablets, oral drugs, ophthalmic injection, detoxification drugs and antiviral medicines. The company sells its products across China. Chengdu Kanghong Pharmaceuticals is headquartered in Chengdu, China.

Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Chengdu Kanghong Enters into Agreement with INC Research 10
Equity Offering 11
Chengdu Kanghong Pharma Raises USD101.2 Million in IPO 11
Acquisition 13
Chengdu Kanghong Pharma Plans to Acquire 7% Stake in Chengdu Based Pharma Unit for USD11 Million 13
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 14
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 15
Chengdu Kanghong Pharmaceuticals Group Co Ltd – Key Competitors 16
Chengdu Kanghong Pharmaceuticals Group Co Ltd – Key Employees 17
Chengdu Kanghong Pharmaceuticals Group Co Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Joint Venture 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chengdu Kanghong Enters into Agreement with INC Research 10
Chengdu Kanghong Pharma Raises USD101.2 Million in IPO 11
Chengdu Kanghong Pharma Plans to Acquire 7% Stake in Chengdu Based Pharma Unit for USD11 Million 13
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 14
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 15
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Key Competitors 16
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Key Employees 17
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Subsidiaries 18
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Joint Venture 18

List of Figures
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chengdu Kanghong Pharmaceuticals Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Petrolympic Ltd (PCQ):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrolympic Ltd (Petrolympic) is an oil and gas exploration and development company that acquires, explores and develops light crude oil and natural gas in North America. The company holds interests in conventional natural gas and light oil projects in Gaspe Peninsula of Quebec. It holds int …
  • Lite-On Technology Corp (2301):企業の財務・戦略的SWOT分析
    Lite-On Technology Corp (2301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Jitsubo Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Jitsubo Co Ltd (Jitsubo), a subsidiary of Sosei Group Corp, is a biotechnology company that develops, manufactures and commercializes peptide therapeutics. The company’s molecular hiving technology modifies the polysaccharide and sugar chain peptide sequence. Its Molecular Hiving technology …
  • Cleco Corporate Holdings LLC:企業の戦略的SWOT分析
    Cleco Corporate Holdings LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Origin Energy Ltd (ORG):企業の財務・戦略的SWOT分析
    Origin Energy Ltd (ORG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Odakyu Electric Railway Co., Ltd. (9007):企業の財務・戦略的SWOT分析
    Odakyu Electric Railway Co., Ltd. (9007) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • BioScrip Inc (BIOS)-医療機器分野:企業M&A・提携分析
    Summary BioScrip Inc (BioScrip), formerly MIM Corp is a healthcare service provider that offers infusion care services. The hospital provides a range of infusion services, PBM services and respiratory services. Its infusion therapy services include antimicrobial drugs, factor replacement therapy for …
  • Ems-Chemie Holding AG (EMSN):企業の財務・戦略的SWOT分析
    Summary Ems-Chemie Holding AG (Ems-Chemie), a subsidiary of Emesta Holding AG, is a chemical company. The company manufactures and markets high performance polymers and specialty chemicals. Its products include bonding products, polyamides, damping systems, sealants, and coating products. Ems-Chemie …
  • C3J Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary C3J Therapeutics Inc (C3J), formerly C3 Jian Inc, is a clinical-stage biotechnology company which concentrates on the development and commercialization of targeted and pathogen specific, antimicrobials that treat and prevent diseases caused by microbial dysbiosis. Its pipeline product portfo …
  • Inpex Corp (1605):石油・ガス:M&Aディール及び事業提携情報
    Summary Inpex Corp (Inpex) is an integrated energy company. It explores for, develops and produces oil and natural gas from its assets in domestic and international regions. The company markets crude oil, condensate, natural gas, and LNG. Inpex has working interest in various upstream projects in Eu …
  • OTE Group:企業の戦略・SWOT・財務分析
    OTE Group - Strategy, SWOT and Corporate Finance Report Summary OTE Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • VertiFlex Inc:医療機器:M&Aディール及び事業提携情報
    Summary VertiFlex Inc (Vertiflex) is a medical device company that offers invasive treatments for lumbar stenosis. The company offers products such as interspinous spacer and direct decompression systems. Its interspinous spacer system is a motion-preserving, indirect decompression spinal implant sy …
  • CareDx Inc (CDNA):医療機器:M&Aディール及び事業提携情報
    Summary CareDx Inc (CareDx), formerly XDx Inc, is a commercial stage molecular diagnostics company that develops, markets, and delivers diagnostic surveillance solutions. The company offers commercialized testing solution, the AlloMap heart transplant molecular test, is a noninvasive blood test used …
  • PowerSouth Energy Cooperative:企業の戦略的SWOT分析
    PowerSouth Energy Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Terumo Corporation:企業の戦略・SWOT・財務分析
    Terumo Corporation - Strategy, SWOT and Corporate Finance Report Summary Terumo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Central Petroleum Ltd (CTP):企業の財務・戦略的SWOT分析
    Summary Central Petroleum Ltd (CPL) operates as an oil and gas company that offers exploration and development services. The company develops, produces, processes and markets hydrocarbons. It operates its oil and gas assets in Amadeus basin, Pedirka basin, Georgina basin, and Wiso basin. CPL’s Amade …
  • Molkerei Meggle Wasserburg GmbH & Co. KG:企業の戦略・SWOT・財務情報
    Molkerei Meggle Wasserburg GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Molkerei Meggle Wasserburg GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Glencore Plc:企業のM&A・事業提携・投資動向
    Glencore Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Glencore Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Kvaerner ASA (KVAER):企業の財務・戦略的SWOT分析
    Kvaerner ASA (KVAER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • David Lloyd Leisure Ltd:企業の戦略・SWOT・財務情報
    David Lloyd Leisure Ltd - Strategy, SWOT and Corporate Finance Report Summary David Lloyd Leisure Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆